A study found a metabolic “off-switch” involved in early pancreatic cancer development.
The research centers on mutations in the KRAS gene. Scientists discovered that reduced activity of two enzymes, G6PD and ME1, lowers production of NADPH, a key molecule that protects cells. This causes a buildup of reactive oxygen species, leading to cell damage and precancerous lesions.
Importantly, G6PD deficiency led to lesions that did not progress, while ME1 deficiency allowed progression to cancer. Antioxidants prevented lesion formation in models. These findings suggest new strategies for early detection and prevention by targeting oxidative stress before cancer develops.